Utilizing the prognostic impact of minimal residual disease in treatment decisions for pediatric acute lymphoblastic leukemia.
Francesco CeppiFrida RizzatiAntonella ColombiniValentino ConterGiovanni CazzanigaPublished in: Expert review of hematology (2021)
Emerging technologies, like next generation flow cytometry, droplet digital PCR, and next generation sequencing appear to be important methods for assessing MRD in pediatric ALL. These more specific and/or sensitive MRD monitoring methods may help to predict relapse with greater accuracy, and are currently being used in clinical trials to improve pediatric ALL outcome by optimizing patient stratification and earlier MRD-based interventional therapy.
Keyphrases
- acute lymphoblastic leukemia
- flow cytometry
- clinical trial
- randomized controlled trial
- case report
- gene expression
- high throughput
- allogeneic hematopoietic stem cell transplantation
- stem cells
- dna methylation
- single cell
- bone marrow
- mesenchymal stem cells
- open label
- young adults
- cell therapy
- combination therapy
- phase iii